ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today ...
The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...
The MarketWatch News Department was not involved in the creation of this content. SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or ...
Want smarter insights in your inbox? Sign up for our weekly newsletters to get only what matters to enterprise AI, data, and security leaders. Subscribe Now (Reuters) — Google said on Thursday it had ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Family physicians are effective in their classifications of diabetic retinopathy using a telemedicine ...
– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New ...
MADISON (WKOW) -- The CDC says nearly 40 million Americans have diabetes, and one in four them will develop some form of blindness from diabetic eye disease, the leading cause of blindness in ...
ROCKVILLE, Md., Aug. 7, 2025 /PRNewswire/ -- REGENXBIO Inc. today announced it will initiate a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) ...
A multicenter randomized controlled trial was conducted to assess the impact of a web-based, diabetes evaluation portal and team-based care on outcomes in patients with diabetic kidney disease. A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results